A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Uterine Sarcoma (HGUtS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment
International Randomised Controlled Trial of Chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
Incorporating the patient voice in sarcoma research: How can we assess quality of life in this heterogeneous group of patients?
A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
In recent years, EORTC has been involved in a number of large practice-changing clinical trials in the field of Soft Tissue and Bone, leading to the registration of drugs to treat sarcomas including gastrointestinal stromal tumors (GIST). The following compounds were investigated within this group (STBSG):
- Imatinib for GIST More information
- Trabectedin for all types of STS
- Pazopanib for non-adipocytic STS More information
- Eribulin for liposarcomas More information More information
Multicentre trials, with large patient numbers to influence clinical practice and address important research topics, evaluated the role of adjuvant chemotherapy in soft tissue sarcoma patients (more information) as well as the role of single-agent doxorubicin versus the combination of doxorubicin plus ifosfamide in advanced and/or metastatic STS patients (more information).
- euroSARC: the synovial sarcoma project EuroJOSS (link) EuroEwing 2012 & rEECurr (link) Joint Action on Rare Cancers
- European Reference Networks (ERN) for rare solid tumours (EURACAN) (link ).
- EORTC-1637 (lms retrospective): retrospective evaluation of first-line treatment for advanced, metastatic or unresectable leiomyosarcomas.
(project leader: lorenzo d’ambrosio)
Status: database open
This is a retrospective research project (rp) to evaluate the activity of doxorubicin as monotherapy as well as in combination with ifosfamide or dacarbazine as first-line treatment for leiomyosarcoma, pleomorphic leiomyosarcoma and undifferentiated sarcoma with smooth muscle differentiation, to potentially guide the design of a prospective randomized study.
As of today, we have already into our database.
Please be noted that we are planning to close the database by the end of march.
- EORTC-1647 (angio. retrospective): retrospective evaluation of adjuvant chemotherapy in angiosarcoma.
(project leader: robin jones)
Research project approved: 23 aug. 2016
The primary objective of the study will be to evaluate the activity of adjuvant chemotherapy in angiosarcoma patients and to potentially guide the design of a prospective randomized study.
Several sites (around 41) from the STBSG are planning to contribute patient data from their clinical practice.
Fondazione IRCCS Istituto Nazionale dei Tumori
Mannheim University Medical Center
The Royal Marsden Hospital
London, United Kingdom
E. Wardelmann - Muenster , DE
Gerhard Domagk Institute of Pathology - University Hospital Muenster
R. Haas - Amsterdam, NL
Chair Local Treatment
The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis
A. Le Cesne - Villejuif, FR
Chair Systemic Treatment
S. Bauer - Essen, DE
Chair Translational Research
Universitaetsklinikum - Essen
C. Messiou - London , GB
Chair Imaging Subcommittee
Royal Marsden Hospital
C. Honoré - Villejuif, FR
W. van den Houdt - London , GB
Royal Marsden Hospital
I. Desar - Nijmegen , NL
Radboud University Medical Center Nijmegen
N. Hindi - Sevilla, ES
Virgen del Rocio University Hospital